SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 131.13% | 74.97% | 39.94% | 14.55% | 2.56% |
| Gross Profit | -131.13% | -74.97% | -42.29% | -14.55% | -6.68% |
| SG&A Expenses | 163.44% | 111.89% | 90.48% | 6.62% | -24.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.21% | 85.64% | 55.78% | 12.11% | -7.00% |
| Operating Income | -140.21% | -85.64% | -57.56% | -12.11% | 4.60% |
| Income Before Tax | -122.37% | -263.09% | -47.97% | 539.11% | -37.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.37% | -263.09% | -47.97% | 539.11% | -37.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.37% | -263.09% | -47.97% | 539.11% | -37.88% |
| EBIT | -140.21% | -85.64% | -57.56% | -12.11% | 4.60% |
| EBITDA | -151.64% | -92.57% | -62.71% | -15.19% | 2.06% |
| EPS Basic | 74.09% | 37.01% | 95.16% | 144.80% | -37.29% |
| Normalized Basic EPS | 74.08% | 37.01% | 71.35% | 481.39% | -37.28% |
| EPS Diluted | 74.09% | 37.01% | 79.60% | 81.02% | -37.29% |
| Normalized Diluted EPS | 74.08% | 37.01% | 71.35% | 152.22% | -37.28% |
| Average Basic Shares Outstanding | 758.07% | 476.42% | 416.56% | 15.13% | 0.43% |
| Average Diluted Shares Outstanding | 758.07% | 476.42% | 416.56% | 740.93% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |